Yüklüyor......
Discovery of compound 1105486 as a selective inhibitor of B4GALT1: potential for pancreatic cancer therapy
Targeting aberrant β-1,4-galactosyltransferase 1 (B4GALT1) activity represents an unexplored therapeutic avenue for pancreatic ductal adenocarcinoma (PDAC). Guided by a concise active-learning structure-based workflow, we rapidly triaged 22.6 million compounds and singled out 1105486 for experimenta...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2025-08-01
|
| Seri Bilgileri: | Frontiers in Chemistry |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fchem.2025.1651402/full |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|